We are excited to announce the 2026 Data Catalyst Award! This award helps offset the cost of RNA profiling experiments for academic researchers. This year’s award prioritizes miRNA biology projects, though applications across RNA biology are welcome.
Selected researchers receive assistance from Eclipsebio to offset the cost of using assays from our RNA profiling portfolio, including miR-eCLIP+. The scope of the funding depends on the project. You keep full ownership of your experimental data. Control datasets generated during your project are de-identified and contributed to our eVERSE database, where they will support both basic research and drug discovery across our partner network.
To apply, fill out the application below. You will be asked in the application to submit a brief description of your miRNA scientific or therapeutic goals. If you pass the initial review, you will meet with our design team to review your project in more detail before final selection.
For any questions about the Data Catalyst Award, application process, or how Eclipsebio supports our partners in their research and drug discovery programs, you can contact us at info@eclipsebio.com.
*To support early-stage innovation, this competition is only available to academic or non-profit researchers.
Latest news
RNA Delivery Prato 2026
Eclipsebio is proud to sponsor the 2026 RNA Delivery Prato meeting to discuss recent discoveries and challenges in RNA delivery.
Eclipsebio Expands eCOMPASS™ Platform with eSENSE Break™ to Map RNA Fragmentation at Nucleotide Resolution
Eclipsebio's eSENSE Break uses sequencing-based analytics to map RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution.
2026 Data Catalyst Award Call for Applications
The Data Catalyst Award helps offset the cost of RNA profiling experiments using Eclipsebio's assays from our RNA profiling portfolio and contributes to the eVERSE database.
Eclipsebio Launches eCOMPASS™, an AI-Enabled Lab-in-the-Loop Platform for RNA Therapeutic Development
Eclipsebio's eCOMPASS platform combines AI-optimized design and sequencing-based analytics to produce successful RNA therapeutics efficiently.